Hologic, Inc.


SKU: HOLX-1 Category:


Hologic, Inc. managed to exceed analyst expectations in terms of revenue as well as earnings, concluding Q4 with total revenue at $945.3 million and non-GAAP earnings per share at $0.89. They showcased exceptional organic growth rates the year, far surpassing long-term targets. The Q4 results highlighted a 16.7% total organic revenue growth, excluding COVID-19, with double-digit growth in all divisions. Breast Health grew by 27.4%, driven by gantry business recovery, while the Diagnostics and Surgical divisions also posted impressive growth rates. The international segment continued to be a significant contributor, growing over 28% organically in Q4. Notably, the company deployed substantial capital for share repurchases in Q4 2023 and Q1 2024, with an additional $500 million accelerated share repurchase program announced. The company’s transformation over the past four years, marked by strategic acquisitions and share repurchases totaling $2.8 billion, positioned it confidently for future success. As Hologic’s team looks to 2024, it anticipates continued growth across divisions, particularly in the Breast Health, Diagnostics, and Surgical segments. They also maintain their global commitment to women’s health, guided by its purpose, passion, and promise. With innovative products, industry-leading margins, and a deep leadership team, they can make a lasting impact on women’s health worldwide.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!